1984 Volume 32 Issue 10 Pages 728-753
In order to comfirm the utility of AT-2266, a new synthetic antimicrobial agent, we carried out a double-blind comparative study with cephalexin compound granules (L-CEX) in the treatment of superficial suppurative skin and soft tissue infections.
A total of 226 cases are participated in the study and 204 cases were evaluated in the efficacy (101 for AT-2266 group and 103 for L-CEX group) and 223 cases in safety (113 for AT-2266 group and 110 for L-CEX group).
Results obtained are as follows;
1) In the evaluation of clinical efficacy, the efficacy rate covering “cured”and “remarkably improved” was 71.3% for AT-2266 group and 73.8% for L-CEX group, and, in addition, the rate including “moderate improved” was 87.1% and 85.4%, respectively. No significant difference was observed between the two groups.
2) As for bacteriological response, no significant difference in the elimination rate was observed; 73.7% for AT-2266 group and 85.7% for L-CEX group. The peaks of MICs of AT-2266 and CEX were 0.78μg/ml and 3.13μg/ml against isolated S. aureus, 0.39μg/ml and 1.56μg/ml against isolated S. epidermidis, respectively.
3) As for safety evaluation, adverse reactions were observed in 11 cases treated with AT-2266 and in 4 cases treated with L-CEX, and abnormal laboratory findings were observed in 2 cases each group (one case in L-CEX group was discontinued). No significant difference was found between AT-2266 group and L-CEX group.
4) In gloval utility rating, according to the clinical efficacy and safety evaluation, the acceptability rate covering “remarkable useful” and “useful” was 74.3% for AT-2266 group and 85.4% for L-CEX group. There was no significant difference between the two groups.
